GU Cancers 2021 | Assessing the impact of ADT in patients with prostate cancer and COVID-19
Tian Zhang, MD, Duke Cancer Center, Durham, NC, discusses the possible impact of androgen deprivation therapy (ADT) on COVID-19 patients with prostate cancer. The androgen-regulated gene TMPRSS2 has been implicated in SARS-CoV-2 viral entry, and therefore ADT was hypothesized to potentially improve COVID-19 outcomes. Across 1005 individuals from the CCC19 analysis, 879 of whom were included in a mortality analysis, no association was found between ADT and improved COVID-19 outcomes in patients with prostate cancer. Further investigations are still on-going. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Tian Zhang, MD, has received research funding from Acerta, Novartis, Merrimack, Abbvie/StemCentrx, Merck, Regeneron, Mirati Therapeutics, Janssen, Astra Zeneca, Pfizer, OmniSeq, Personal Genome Diagnostics and Astellas; has been a speaker for Sanofi-Aventis and Genomic Health; has participated in advisory boards for Genentech/Roche, Merck, Exelixis, Sanofi-Aaventis, Janssen, Astra Zeneca, Pfizer, Amgen, BMS, Pharmacyclics, Seattle Genetics, Dendreon and Calithera; has done consultancy work for Bayer, Astra Zeneca, Foundation Medicine, IQVIA, MJH Associates, Pacific Genuity; and has familial connections to Nanorobotics, Capio Biosciences and Archimmune Therapeutics (spouse).
